Indegene Limited reported mixed financial results for Q4 and the full year ended March 31, 2026, demonstrating strong revenue performance while experiencing a decline in quarterly net profit. The company crossed significant milestones, surpassing ₹1,000 crore in quarterly revenue for the first time and achieving ₹3,500 crore for the full year. The Board of Directors approved the audited standalone and consolidated financial results on April 29, 2026. Additionally, the company has made available the audio recording of the Q4 and Annual FY26 Earnings Call conducted on April 30, 2026, pursuant to Regulation 30 and 46(2)(o) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Q4 FY26 Performance

The fourth quarter showed robust revenue momentum with revenue from operations of ₹10,034 million, up 32.8% YoY and 6.5% QoQ. However, the company's Q4 consolidated net profit declined to ₹797 million compared to ₹1.2 billion in the same quarter last year. In USD terms, Q4 revenue stood at $109.7 million, representing 25.6% YoY growth. Adjusted EBITDA for Q4 FY26 was ₹1,889 million, up 23.2% YoY with an 18.8% margin.

Full-Year FY26 Highlights

For the financial year ended March 31, 2026, consolidated revenue from operations reached ₹35,105 million, compared to ₹28,393 million in the previous year, representing 23.6% YoY growth. In USD terms, full-year revenue stood at $396.9 million, up 18.2% YoY. Adjusted EBITDA for FY26 was ₹6,793 million at 19.4% margin, up 20.8% YoY. Cash flow from operations showed significant strength at ₹6,508 million, up 47.3% YoY.

Earnings Call Audio Recording Availability

Pursuant to regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Indegene Limited has made available the audio recording of the Q4 and Annual FY26 Earnings Call conducted on April 30, 2026. The recording can be accessed through the company's official website and provides detailed insights into the financial performance and management commentary.

Management Outlook and Strategic Direction

During the conference call, management provided guidance on margin recovery, indicating that EBITDA margins are set to return to higher levels in H2 FY 2027. This improvement is expected to be backed by a robust pipeline of outcome-based contracts and the ongoing integration of the Biopharm acquisition. The company's strategic focus on outcome-based engagements and the successful integration of acquired capabilities are expected to drive margin expansion in the coming periods.

Operational Metrics and Strategic Progress

FY26 marked a landmark year with active client relationships growing to 91 from 73 in FY25. The company achieved industry-leading revenue per employee of approximately $75,000. A total of 53 clients contributed over $1 million in annual revenue, up from 41 in FY25. Net Revenue Retention (NRR) stood at 105.8% for FY26. The company's cash conversion ratio reached 162%, reflecting strong underlying cash generation. The company reported strong bookings with 1 deal exceeding $3 million in annual contract value and 7 deals in the $1-3 million range.

Dividend Recommendation

The Board of Directors has recommended a final dividend of ₹2.25 per equity share for the financial year ended March 31, 2026, representing a 12.5% increase over FY25. The proposed dividend will be paid within 30 days after approval by shareholders at the ensuing Annual General Meeting. If approved, the dividend would result in a cash outflow of approximately ₹542 million.

Management Commentary

"FY26 was a landmark year for Indegene. We surpassed ₹1,000 crore in quarterly revenue for the first time, and ₹3,500 crore for the full year," said Manish Gupta, Chairman and CEO, Indegene. "This reflects growing strategic depth in our largest client relationships, with 53 clients contributing over $1M in annual revenue, alongside breakthrough GenAI-led wins across Commercial and Medical."

"FY26 reflected disciplined financial execution. Our cash conversion ratio of 162% reflects continued strong underlying cash generation," said Suhas Prabhu, CFO, Indegene. "Reflecting this strength, the Board has recommended a final dividend of ₹2.25 per share - a 12.5% increase over FY25."

Indegene Limited has formally announced its Q4 and Annual FY26 earnings conference call through an official communication to stock exchanges on April 22, 2026. The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, providing stakeholders with an opportunity to engage with senior management regarding the company's financial performance.

Earnings Call Schedule and Details

The earnings conference call has been scheduled for Thursday, April 30, 2026, at 8:00 AM IST. This timing allows both domestic and international investors to participate in the discussion regarding Indegene's quarterly and annual financial results.

Management Participation

The earnings call will feature key members of Indegene's senior leadership team who will present the financial results and address investor queries. The company has confirmed participation from top executives to ensure comprehensive coverage of business performance and strategic initiatives.

Access Information for Participants

Indegene has provided multiple access options for participants to join the earnings conference call. The company has established universal access numbers and offers early registration through DiamondPass for enhanced convenience.

Regulatory Compliance

The earnings call announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Srishti Ramesh Kaushik signed the official communication on April 22, 2026. The company has noted that the announced schedule remains subject to changes, if any, and will keep stakeholders informed of any modifications.